Harvard Bioscience, Inc. (NASDAQ:HBIO) Sees Large Decrease in Short Interest

Harvard Bioscience, Inc. (NASDAQ:HBIO) was the target of a significant decline in short interest during the month of November. As of November 15th, there was short interest totalling 374,100 shares, a decline of 6.2% from the October 31st total of 398,900 shares. Based on an average daily trading volume, of 136,800 shares, the days-to-cover ratio is presently 2.7 days.

Harvard Bioscience Stock Performance

Shares of Harvard Bioscience stock opened at $2.24 on Wednesday. The stock has a market cap of $97.71 million, a price-to-earnings ratio of -6.79 and a beta of 1.27. The firm’s 50-day moving average is $2.38 and its 200 day moving average is $2.77. Harvard Bioscience has a 1 year low of $1.99 and a 1 year high of $5.56. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.06 and a quick ratio of 0.91.

Institutional Investors Weigh In On Harvard Bioscience

Several institutional investors have recently modified their holdings of HBIO. GSA Capital Partners LLP bought a new position in Harvard Bioscience during the 3rd quarter valued at about $30,000. Allspring Global Investments Holdings LLC purchased a new position in shares of Harvard Bioscience during the second quarter valued at approximately $31,000. SG Americas Securities LLC bought a new position in Harvard Bioscience during the third quarter valued at approximately $36,000. Avior Wealth Management LLC lifted its position in Harvard Bioscience by 1,118.1% during the third quarter. Avior Wealth Management LLC now owns 14,569 shares of the medical instruments supplier’s stock valued at $39,000 after purchasing an additional 13,373 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new stake in Harvard Bioscience in the second quarter worth approximately $40,000. 80.87% of the stock is owned by hedge funds and other institutional investors.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.